See more : Bluejay Diagnostics, Inc. (BJDX) Income Statement Analysis – Financial Results
Complete financial analysis of Immuneering Corporation (IMRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immuneering Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- African Pioneer PLC (AFP.L) Income Statement Analysis – Financial Results
- Biotech Acquisition Company (BIOTU) Income Statement Analysis – Financial Results
- Digital Media Solutions, Inc. (DMS-WT) Income Statement Analysis – Financial Results
- Genetic Technologies Limited (GENE) Income Statement Analysis – Financial Results
- 1 Production Film Co. (8458.TWO) Income Statement Analysis – Financial Results
Immuneering Corporation (IMRX)
About Immuneering Corporation
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 316.95K | 2.08M | 2.31M | 1.92M |
| Cost of Revenue | 764.14K | 158.12K | 1.15M | 1.28M | 1.22M |
| Gross Profit | -764.14K | 158.83K | 926.89K | 1.03M | 696.74K |
| Gross Profit Ratio | 0.00% | 50.11% | 44.56% | 44.61% | 36.29% |
| Research & Development | 41.40M | 36.27M | 26.54M | 15.00M | 4.28M |
| General & Administrative | 16.76M | 15.61M | 8.27M | 3.11M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.76M | 15.61M | 8.27M | 3.11M | 2.71M |
| Other Expenses | 0.00 | 30.05K | -127.06K | 0.00 | 0.00 |
| Operating Expenses | 58.41M | 51.90M | 34.81M | 18.11M | 6.99M |
| Cost & Expenses | 58.41M | 52.06M | 35.97M | 19.39M | 8.21M |
| Interest Income | 3.61M | 1.01M | 169.90K | 42.66K | 57.66K |
| Interest Expense | 0.00 | 1.01M | 0.00 | 0.00 | 351.30K |
| Depreciation & Amortization | 352.08K | 796.79K | 159.07K | 79.31K | 18.08K |
| EBITDA | -58.06M | -51.47M | -33.68M | -17.00M | -7.34M |
| EBITDA Ratio | 0.00% | -16,316.29% | -1,629.17% | -733.74% | -382.35% |
| Operating Income | -58.41M | -51.74M | -33.89M | -17.08M | -6.29M |
| Operating Income Ratio | 0.00% | -16,325.77% | -1,629.17% | -739.01% | -327.71% |
| Total Other Income/Expenses | 4.94M | 1.23M | 42.84K | 42.66K | -1.42M |
| Income Before Tax | -53.47M | -50.51M | -33.84M | -17.04M | -7.71M |
| Income Before Tax Ratio | 0.00% | -15,937.29% | -1,627.11% | -737.17% | -401.59% |
| Income Tax Expense | 0.00 | -1.23M | -307.49K | -84.34K | 351.30K |
| Net Income | -53.47M | -49.28M | -33.54M | -17.04M | -8.06M |
| Net Income Ratio | 0.00% | -15,548.66% | -1,612.33% | -737.17% | -419.89% |
| EPS | -1.88 | -1.87 | -1.27 | -0.67 | -0.32 |
| EPS Diluted | -1.88 | -1.87 | -1.27 | -0.67 | -0.32 |
| Weighted Avg Shares Out | 28.42M | 26.39M | 26.32M | 25.51M | 25.51M |
| Weighted Avg Shares Out (Dil) | 28.42M | 26.39M | 26.32M | 25.51M | 25.51M |
Immuneering Announces Participation in November Investor Conferences
CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced that management...
These Are the Five Best and Worst Performing Small-cap Stocks in September 2022
Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.
Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced it will...
What Makes Immuneering Corporation (IMRX) a New Buy Stock
Immuneering Corporation (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 148% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104
Immuneering (IMRX) files an investigational new drug (IND) application to the FDA to start a phase I/IIa study on IMM-1-104 for the treatment of advanced RAS mutant solid tumors. Stock up.
Immuneering Announces Participation in September Investor Conferences
CAMBRIDGE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today announced that...
Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue Estimates
Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 15.38% and 65.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Immuneering Announces Participation in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today announced that...
Source: https://incomestatements.info
Category: Stock Reports